We are live on ! Find out more
PNT

POINT Biopharma Global Inc. Common Stock
PNT

Delisted

PNT was delisted on the 26th of December, 2023.

Back to rankings

106 hedge funds and large institutions have $470M invested in POINT Biopharma Global Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

90% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 21

42% more capital invested

Capital invested by funds: $330M → $470M (+$140M)

26% more funds holding

Funds holding: 84 → 106 (+22)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
106
Holders Change
+22
Holders Change %
+26.19%
% of All Funds
1.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
32
Increased
40
Reduced
21
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$38.3M
2
APM
Avidity Partners Management
Texas
+$23.9M
3
BI
BVF Inc
California
+$18.9M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$14.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$11.6M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$61.3M
2
SCM
Suvretta Capital Management
New York
-$5.8M
3
PA
Perceptive Advisors
New York
-$4.87M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$3.95M
5
RI
RTW Investments
New York
-$3.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$2.79M +$3.06M +360,861 New
PAMP
27
Polar Asset Management Partners
Ontario, Canada
$2.71M +$1.26M +147,900 +73%
Alyeska Investment Group
28
Alyeska Investment Group
Illinois
$2.68M -$3.95M -465,207 -57%
SCM
29
Silverarc Capital Management
Massachusetts
$2.32M +$2.55M +300,000 New
N
30
Nuveen
North Carolina
$2.03M -$17.3K -2,035 -0.8%
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$1.91M +$4.36K +514 +0.2%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.74M +$180K +21,159 +10%
NCM
33
Nantahala Capital Management
Connecticut
$1.53M +$1.68M +197,783 New
Charles Schwab
34
Charles Schwab
California
$1.49M +$3.74K +441 +0.2%
Invesco
35
Invesco
Georgia
$1.41M -$22.4K -2,640 -1%
Bank of America
36
Bank of America
North Carolina
$1.39M +$777K +91,529 +103%
Goldman Sachs
37
Goldman Sachs
New York
$1.38M -$1.87M -220,111 -55%
Swiss National Bank
38
Swiss National Bank
Switzerland
$1.23M +$542K +63,800 +67%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$1.15M +$767K +90,366 +155%
BFS
40
Baskin Financial Services
Ontario, Canada
$1.11M -$305K -35,872 -20%
Citigroup
41
Citigroup
New York
$1.08M +$651K +76,730 +122%
Walleye Capital
42
Walleye Capital
New York
$1.01M -$766K -90,270 -41%
Fisher Asset Management
43
Fisher Asset Management
Washington
$919K +$1.01M +118,906 New
Marshall Wace
44
Marshall Wace
United Kingdom
$890K +$977K +115,102 New
Barclays
45
Barclays
United Kingdom
$733K +$659K +77,674 +453%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$718K +$55.9K +6,580 +8%
CSS
47
Cubist Systematic Strategies
Connecticut
$681K +$734K +86,484 +5,405%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$676K +$178K +20,998 +32%
LPL Financial
49
LPL Financial
California
$611K +$485K +57,160 +261%
BFM
50
Boothbay Fund Management
New York
$603K +$662K +78,015 New
1
2
3 4 5

PNT Hedge Fund Activity: Q3 2022 in Review

106 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2022, worth a combined $470M — up 42% from $330M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new PNT positions and 10 closed out — a net gain of 22 holders — while 40 added to existing stakes and 21 trimmed.

The largest buyer was PFM Health Sciences, opening a new position worth an estimated $38.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $61.3M sold.

  • 106 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2022, up from 84 in Q2 2022.
  • Funds reported $470M of POINT Biopharma Global Inc. Common Stock stock for Q3 2022, up 42% quarter-over-quarter.
  • 32 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2022 and 10 closed out, a net change of +22 holders.
  • The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2022 was PFM Health Sciences, an estimated $38.3M added.
  • The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2022 was RA Capital Management, an estimated $61.3M sold.

Based on aggregated 13F filings for Q3 2022.